www.zejournal.mobi
December 22, 2024

YouTube censors video of Nobel Prize winner Dr. Satoshi Omura discussing ivermectin

Author : Tom Parker | Editor : Anty | July 05, 2021 at 08:33 AM

Before the coronavirus pandemic, ivermectin was described as a “wonder” drug by the medical community. And in 2015, Dr. Satoshi ?mura and Dr. William C. Campbell were awarded half the Nobel prize in Physiology or Medicine for their work that led to the development of ivermectin.

“The importance of Ivermectin for improving the health and wellbeing of millions of individuals with River Blindness and Lymphatic Filariasis, primarily in the poorest regions of the world, is immeasurable,” the Nobel Assembly stated in its press release for the 2015 Nobel Prize in Physiology or Medicine.

But after the pandemic began, the tech giants have gone all out to purge content that recommends ivermectin as a treatment for COVID-19.

And today, these Big Tech policies against ivermectin resulted in one of ?mura’s speeches where he discussed ivermectin being struck down for “violating YouTube’s community guidelines.”

“When the fascists at YouTube censor the Noble Prize winner Dr. Satoshi Omura, a man whose discoveries have saved a hundred million + from blindness, the world has entered a very, very dark place,” Australian Member of Parliament Craig Kelly tweeted. “I cannot express in words how angry & sad this makes me & fearful for the future.”

Frontline Covid-19 Critical Care, an alliance of physicians and scholars that has committed to “research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness,” also spoke out against the censorship and warned that “brilliant scientists and lifesaving science are systematically being gagged.”

?mura joins the ranks of many other senatorslawmakersmedical journalsbiologists, and YouTubers who have been censored by Big Tech for discussing ivermectin.


Read More :


- Source : Tom Parker

Send via email :

Comment

Send your comment via :



Close

Search
Like Our Site?
(34)
Latest Articles
Most Read Articles
Loading...
Loading...
Loading...

Email Subscribe

Received our newsletter, we send it to your email

  


Close